The elevated expression of KAT2A in PCa tissues was found to be significantly correlated with poor clinical outcomes in PCa patients and also promoted resistance to arbiterone treatment in CRPC abiraterone therapy in CRPC. The gene discussed is KAT2A; the disease is posterior cortical atrophy.